Skip to Main content Skip to Navigation
Journal articles

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer

Abstract : Interleukin (IL)-15 has an important role in tumor immuno-surveillance and has a contemplated use in tumor immu-notherapy. We have previously engineered the fusion protein RLI, composed of the NH 2-terminal (amino acids 1-77, sushi+) domain of IL-15 receptor α coupled via a linker to IL-15, and shown that it displayed far better efficacy than IL-15 in vitro. In this report, we investigated in vivo whether RLI would be a better alternative than IL-15 and IL-2 for cancer treatment using two distinct animal models. B16F10 mouse melanoma cells were injected in C57BL/6 mice either i.v. or intrasplenically for lung or liver metastasis, respectively. HCT-116 human co-lorectal cancer cells were injected in the cecum of nude mice. We show that RLI has a higher efficiency than IL-15 or IL-2 to reduce lung and liver metastasis and enhance survival in the mouse B16F10 melanoma model, a result that was associated with a higher half-life in vivo. We also found that the antitumoral effect of RLI was completely abolished by in vivo depletion of natural killer cells using anti-asialoGM1 antibody. Moreover, RLI was also efficient to reduce by 50% tumor growth and the progression of metastasis of human colon carcinoma cells in an orthotopic nude mouse model. The fusion protein RLI has revealed strong anticancer effect in two different cancer models overcoming the limited effect of IL-15 by increasing its bioavailability and efficiency. These findings hold significant importance for the use of RLI as a potential adjuvant/therapeutic. [Mol Cancer Ther 2009;8(9):2736-45]
Document type :
Journal articles
Complete list of metadata

Cited literature [46 references]  Display  Hide  Download
Contributor : Agnès QUEMENER Connect in order to contact the contributor
Submitted on : Wednesday, January 15, 2020 - 1:14:07 PM
Last modification on : Wednesday, November 10, 2021 - 3:32:04 PM
Long-term archiving on: : Thursday, April 16, 2020 - 3:23:28 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Anne Bessard, Véronique Solé, Grégory Bouchaud, Agnès Quéméner, Yannick Jacques. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer. Molecular Cancer Therapeutics, American Association for Cancer Research, 2009, 8 (9), pp.2736-2745. ⟨10.1158/1535-7163.MCT-09-0275⟩. ⟨inserm-02440759⟩



Record views